CMPX
CMPX clinical trials: Compass Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Compass Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 10
- Trials linked
- 6
- As lead sponsor
- 4
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
CMPX on the catalyst calendar · CMPX registry changes
- Primary completion Sep 2028Sponsor estimatePhase 2NCT07684170Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine NeoplasmsCompass Therapeutics · Neuroendocrine NeoplasmRecruitingCMPXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 31, 2027Sponsor estimatePhase 2/Phase 3NCT05506943A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract...Compass Therapeutics · Biliary Tract CancerActive, not recruitingCMPXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT06150664A Phase 1 of CTX-8371 in Patients With Advanced MalignanciesCompass Therapeutics · Non Small Cell Lung CancerRecruitingCMPXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 1, 2028Sponsor estimatePhase 1NCT07419841A Phase 1 Study of the Safety and Tolerability of CTX-10726Compass Therapeutics · Gastroesophageal Cancer (GC)RecruitingCMPXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 15, 2025ActualPhase 2NCT05513742A Study of CTX-009 in Adult Patients With Metastatic Colorectal CancerCompass Therapeutics · Metastatic Colorectal CancerCompletedCMPXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 21, 2025ActualPhase 1NCT03881488Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally...Compass Therapeutics · Locally Advanced Solid TumorTerminatedCMPXLeadIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2030Sponsor estimatePhase 2NCT07662031Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal CancerWashington University School of Medicine · Colorectal CancerNot yet recruitingCMPXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 1, 2027Sponsor estimatePhase 1/Phase 2NCT06548412CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract CancersM.D. Anderson Cancer Center · Metastatic Biliary Tract CancerRecruitingCMPXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2029Sponsor estimatePhase 1/Phase 2NCT07392957Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent GlioblastomaWashington University School of Medicine · GlioblastomaRecruitingCMPXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 8, 2024ActualPhase 1/Phase 2NCT04492033A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor PatientsHandok Inc. · P1b: Advanced Solid TumorsTerminatedCMPXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner